Carcinotech

Executive Summary

Carcinotech is a UK-based preclinical oncology services company that has developed a proprietary 3D bioprinting platform to create patient-derived tumor models. These models closely mimic the native tumor microenvironment, offering a more physiologically relevant system for cancer drug discovery and personalized treatment testing compared to traditional 2D cultures or animal models. By retaining key cellular and stromal components, Carcinotech's models enable more accurate prediction of drug efficacy and toxicity, thereby reducing the high failure rates of oncology drugs in clinical trials. The company serves pharmaceutical and biotech clients with end-to-end services including model sourcing, development, and custom assay execution. The global demand for more predictive preclinical models is escalating as the pharmaceutical industry seeks to de-risk drug development and embrace precision medicine. Carcinotech's platform addresses this need by providing human-specific, patient-relevant models that can be deployed at scale. With a focus on high-quality, reproducible data, the company is well-positioned to capture market share in the growing 3D cell culture and organ-on-a-chip sectors. As Carcinotech continues to validate its technology through client engagements and peer-reviewed studies, it is poised for growth through strategic partnerships and potential fundraising to scale operations and expand its service offerings.

Upcoming Catalysts (preview)

• Q3 2026Partnership with Top-20 Pharma Company50% success
• Q4 2026Series A Funding Round60% success
• Q2 2026Launch of High-Throughput Screening Service70% success